Navigation Links
Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
Date:10/20/2010

LONDON, Oct. 20 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the "Zamore Design Rules."  European patent number 1 633 890 titled "Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi" was published today in the European Patent Bulletin.  The European patent covers various breakthrough structural modification methods and compositions which Silence believes are fundamental for the development and commercialization of RNAi therapeutics with enhanced efficacy.

"The granting of this comprehensive patent in Europe is a significant milestone for Silence in our ongoing effort to build one of the world's leading RNAi intellectual property positions.  We have consistently built a strong IP estate around the Zamore technology in the U.S. and have now extended our global coverage to Europe with the granting of this critical patent," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We have often stated our belief that the 'Zamore Design Rules' represent significant IP to enable the process of bringing effective RNAi therapeutics to market.  With this latest patent grant from the EPO, we are excited to be able to offer potential collaborators or licensing partners access to this strongly protected Zamore technology in both the U.S. and Europe."

The issued patent's method and composition claims include:

  • Methods of enhancing the ability of an antisense strand of an RNAi agent to act as a guide strand
  • RNAi or siRNA agents for enhancing silencing of a target mRNA in a subject
  • Compositions for siRNA duplexes include pre-miRNA and shRNA and vectors to perform the methods described herein

Silence owns excl
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
2. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
3. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
4. Silence Therapeutics Appoints New Vice President of Research
5. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
8. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
9. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
10. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
11. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Research and Markets has announced the addition ... (GPC) Industry Report 2014" report to their offering. ... Chromatography (GPC) Industry Report is a professional and in-depth ... permeation chromatography industry with a focus on the Chinese ... the industry including definitions, classifications, applications and industry chain ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... 2014 The AMA is pleased to ... in Alaska that Alaska Governor Sean Parnell has signed ... defining public use of Unmanned Aircraft Systems and the ... Bill 255states that it is, “An Act relating to ... an unmanned aircraft system.” It defines State of Alaska ...
(Date:8/22/2014)... August 22, 2014 Nerium International, ... is in the spotlight again. Nerium will showcase ... its NeriumFirmTM Body Contouring Cream to Hollywood’s elite ... Creations during the 66th Primetime Emmy® Awards. , ... extract, third-party clinical trials show that NeriumAD night ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3State of Alaska Signs Unmanned Aircraft Systems Bill 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3
... Biotech Product with ... Direct Consumer Benefits, DES MOINES, Iowa, ... oil trait from DuPont (NYSE: DD ),will deliver increased nutritional ... market. The high oleic soybean,oil trait is the next generation of ...
... Data presented at AAAAI 64th Annual Meeting also show ... effective treatment for HAE attacks across all body sites, ... a safe and effective therapy that rapidly relieves acute,abdominal ... a rare and serious genetic disorder, according to data,presented ...
... March 18 /PRNewswire/ - Aegera Therapeutics announced ... clinical trial for AEG33773, a,novel, orally bioavailable ... painful diabetic neuropathy. The Phase I study ... of AEG33773 using a randomized,double blind, placebo ...
Cached Biology Technology:Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 2Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:8/22/2014)... (Maximizing Access to Research Careers) Program has announced the ... & Practical Exercises Workshop which will be held on ... 25-26, 2014. These awards are meant to help ... underrepresented groups in the the FASEB Grant Writing Seminar ... 11 awards totaling $20,350. , The FASEB MARC Program ...
(Date:8/22/2014)... can probably remember the after-effects, including pain, swelling or ... back against the injury. When tissue in the body ... tissue regeneration. An inflammatory response acts as a protective ... to heal after injuries such as wounds and burns. ... situations in which foreign material is introduced, for example ...
(Date:8/22/2014)... important discoveries in basic and clinical research and ... into a complex offensive spanning multiple fronts. , ... lab could help find new and more selective ... that targets a specific enzyme overexpressed in certain ... from brain tumours. , Chemistry professor Christopher Cairo ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Using an extremely sensitive measurement technique, researchers at ... a lead-specific DNAzyme uses the lock and key reaction ... the same DNAzyme uses the induced fit reaction ... and key mechanism explains why this particular lead-specific DNAzyme ...
... Molecular Biology Laboratory [EMBL] announces Luxembourg as the ... EMBL,s council and ratified by the parliament of ... as the 20th member state. "EMBL is ... Franois Biltgen, Minister of Culture, Higher Education and ...
... researchers have engineered with a novel inkjet printing method ... harmful industrial solvents and explosives. Led by MIT ... to print thin sensor films onto a microchip, a ... highly sensitive gas detectors. Mass production would ...
Cached Biology News:The key to unlocking the secret of highly specific DNAzyme catalysis 2Luxembourg joins EMBL 2MIT's 'electronic nose' could detect hazards 2MIT's 'electronic nose' could detect hazards 3
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... for spontaneous ligand immobilization can be coupled with ... or receptor to create an affinity matrix of ... ligands via primary amines. Affi-Gel 10 gel couples ... to 11; Affi-Gel 15 gel couples acidic proteins ...
Biology Products: